ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

QurAlis raises $42 million to develop ALS drugs

by Ryan Cross
May 15, 2020 | APPEARED IN VOLUME 98, ISSUE 19

 

QurAlis, a start-up based in Cambridge, Massachusetts, has raised $42 million in series A financing to develop small-molecule and antisense oligonucleotide drugs for two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The company plans to discover drugs that individually target one of nearly 30 genes implicated in ALS. Many of these genes are also implicated in FTD. Its lead programs are focused on drugging a potassium channel and an enzyme that regulates autophagy.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment